Association between SLC2A9 Genetic Variants and Risk of Hyperuricemia in a Uygur Population

Sun, Yan; Xu, Fei; Yan, Dandan; Kahaer, Mayina; Zhang, Xiaojin; Guo, Yong; Hu, Cheng; Jia, Weiping; Luo, Li

doi:10.1007/s11596-019-2026-2

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GLUT9, encoded by the SLC2A9 gene, is a glucose transporter gene expressed primarily in the liver and kidney. Genome-wide studies in several countries have demonstrated that SLC2A9 gene polymorphisms are associated with SUA levels [7]. A meta-analysis of genome-wide association scans in 28,141 people of European descent showed that the SLC2A9 rs734553 T allele might be the strongest marker of elevated SUA described to date [8].…”

Section: What Is Known and Objectivementioning

confidence: 99%

SLC2A9 Gene Polymorphism Is Associated with Elevated Serum Uric Acid Caused by Pyrazinamide

Dai

Wang

Wu³

et al. 2023

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

What Is Known and Objective. Elevated serum uric acid (SUA) is one of the most common adverse reactions during the administration of pyrazinamide, but patients exhibit significant individual differences. This study aimed to evaluate the relationship between gene polymorphisms and pyrazinamide-induced SUA elevation in Han Chinese tuberculosis patients. Methods. Tuberculosis patients treated with pyrazinamide were genotyped for the following three candidate genes: SLC22A12, SLC2A9, and ABCG2. Patients were divided into low-risk and high-risk groups according to the change of SUA after treatment. Intergroup comparisons were performed on clinical characteristics, allele and genotype frequencies, and haplotype distributions, and logistic regression analysis was used to explore the relevant risk factors. Results. In total, 143 patients were enrolled, including 83 in the high-risk groups and 60 in the low-risk groups. We observed a significant association between SLC2A9 polymorphism and pyrazinamide-induced SUA elevation. The G allele was significantly lower in the high-risk group than in the low-risk group (27.7% vs. 48.3%, OR = 0.410, 95% CI: 0.250–0.671, p < 0.001 ). Patients with the GA and GG genotypes were less likely to have SUA elevation than those with the AA genotype (OR = 0.125, 95% CI: 0.053–0.293, p < 0.001 and OR = 0.252, 95% CI: 0.074–0.851, p = 0.026 , respectively). Regarding SLC2A9 rs13129697, the frequency of the G allele was significantly lower in the high-risk group than in the low-risk group (26.1% vs. 40.8%, OR = 0.531, 95% CI: 0.312–0.842, p = 0.008 ). In the low-risk group, the proportion of patients with the TG genotype was significantly higher than that with the TT genotype (81.7% vs. 18.3%, OR = 0.279, 95% CI: 0.127–0.611, p = 0.001 ). Haplotype analysis revealed that patients with the SLC2A9 (rs1014290–rs13129697) GG haplotype had lower risk of SUA elevation than those with the AT haplotype (27.11% vs. 63.25%, p = 0.005 ). Furthermore, logistic regression analysis showed that drinking history was an independent risk factor for elevated SUA caused by PZA (OR = 3.943, 95% CI = 1.18–13.175, p = 0.026 ) and that the rs1014290 GA genotype might be a protective factor (OR = 0.094, 95% CI = 0.023–0.386, p = 0.001 ) after correction. What Is New and Conclusion. We found that SLC2A9 genetic polymorphisms were associated with elevated SUA caused by pyrazinamide. The G>A variant of rs1014290 and drinking history might be risk factors.

show abstract

Section: What Is Known and Objectivementioning

confidence: 99%

SLC2A9 Gene Polymorphism Is Associated with Elevated Serum Uric Acid Caused by Pyrazinamide

Dai

Wang

Wu³

et al. 2023

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that SLC2A9 has >60 variant sites [ 15 ]. These studies explored mainly the correlation between single nucleotide polymorphisms (SNPs) in SLC2A9 and hyperuricemia and gout [ 16 , 17 ], but a few of them focused on T2DM. One study in a Taiwan Han population showed that SNP rs1014290 in the third intron of SLC2A9 was associated with T2DM [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

SLC2A9 rs1014290 Polymorphism is Associated with Prediabetes and Type 2 Diabetes

Zhang

Hou

et al. 2022

International Journal of Endocrinology

View full text Add to dashboard Cite

Purpose. To investigate the association of the A/G rs1014290 polymorphism in SLC2A9 with type 2 diabetes (T2DM) and prediabetes mellitus (pre-DM). Patients and Methods. We enrolled 1058 patients who attended the Hebei General Hospital, Shijiazhuang, Hebei Province, China. The patients underwent general testing and oral glucose tolerance tests and were divided into three groups: 352 patients newly diagnosed with T2DM, 358 patients with pre-DM, and 348 healthy controls. The single nucleotide polymorphism (SNP) was detected by ligase detection reactions. The χ2 test, one-way ANOVA, and binary logistic regression analysis were used to analyze the results. Results. In the T2DM group, the GG genotype frequency at the rs1014290 locus was significantly lower (14.8%) than it was in the healthy controls. Furthermore, the GG genotype group was associated with a reduced risk of T2DM in unadjusted and confounder-adjusted models compared with the risk in the AA genotype group. The G allele in the SLC2A9 rs1014290 locus decreased susceptibility to T2DM. In the pre-DM group, the GG and AG genotype groups had no significant correlation with the risk of pre-DM in any of the models. In the T2DM group, the uric acid level was significantly lower in the GG genotype group. In the T2DM and pre-DM groups, the HOMA-β levels were significantly higher in the GA ( P < 0.001 ) and GG ( P < 0.001 ) genotype groups than it was in the AA genotype group, and HOMA-IR was significantly lower in the GA ( P < 0.001 ) and GG ( P < 0.001 ) genotype groups than it was in the AA genotype group. Conclusion. The A/G (rs1014290) SNP in SLC2A9 is closely related to the occurrence and development of diabetes.

show abstract

Association between SLC2A9 Genetic Variants and Risk of Hyperuricemia in a Uygur Population

Cited by 2 publications

References 19 publications

SLC2A9 Gene Polymorphism Is Associated with Elevated Serum Uric Acid Caused by Pyrazinamide

SLC2A9 Gene Polymorphism Is Associated with Elevated Serum Uric Acid Caused by Pyrazinamide

SLC2A9 rs1014290 Polymorphism is Associated with Prediabetes and Type 2 Diabetes

Contact Info

Product

Resources

About